New results from a subgroup analysis of the ICONIC-LEAD study showed icotrokinra was effective and safe for the treatment of moderate to severe plaque psoriasis in adolescents, according to a press ...

Psoriasis shows on the skin, but it's a disease which goes a lot deeper and is linked to serious health problems. In recent years, newer targeted drugs are making a difference.

Deucravacitinib has been observed as a safe and efficacious treatment for adults with moderate to severe plaque psoriasis for up to 4 years.

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

Psoriasis doesn’t prevent you from having a cosmetic procedure, but there are safety and timing concerns to consider. Learn ...

BIOLOGIC therapies significantly reduce the risk of major adverse cardiovascular events (MACEs) in patients with psoriasis and psoriatic arthritis (PsA), offering potential heart health benefits ...

Korea: A recent retrospective cohort study published in the Journal of the American Academy of Dermatology explored the link between biologic and nonbiologic systemic therapies for psoriasis and ...

Having stripped back its workforce, antibiotics biotech Spero Therapeutics continues to strip away its remaining pipeline. The latest program to be discontinued is SPR206, a next-gen polymyxin ...